Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Immune thrombocytopenia (ITP) medications" to "Category:Immune thrombocytopenia medications") |
m |
||
| Line 2: | Line 2: | ||
Thrombopoietin receptor agonist | Thrombopoietin receptor agonist | ||
| − | ==Diseases for which it is | + | ==Diseases for which it is established== |
*[[Immune thrombocytopenia (ITP)]] | *[[Immune thrombocytopenia (ITP)]] | ||
*[[Thrombocytopenia in liver disease]] | *[[Thrombocytopenia in liver disease]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 5/21/2018: | + | * 5/21/2018: Approved for [[Thrombocytopenia in liver disease|thrombocytopenia in adults with chronic liver disease]] scheduled to undergo a procedure. |
| + | ==History of changes in EMA indication== | ||
| + | *6/20/2019: Initial authorization as Doptelet | ||
| + | *Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. | ||
| + | *Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). | ||
==Also known as== | ==Also known as== | ||
| Line 23: | Line 27: | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
| + | [[Category:EMA approved in 2019]] | ||
Revision as of 13:14, 3 January 2023
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is established
History of changes in FDA indication
- 5/21/2018: Approved for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
History of changes in EMA indication
- 6/20/2019: Initial authorization as Doptelet
- Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
- Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Also known as
- Code names: E5501, YM477, AKR 501
- Brand name: Doptelet